We are live on ! Find out more
WCBA

Weaver C. Barksdale & Associates Portfolio holdings

AUM $105M
1-Year Est. Return 13.81%
This Fund
S&P 500
This Quarter Est. Return
+0.33%
1 Year Est. Return
+13.81%
3 Year Est. Return
+40.08%
5 Year Est. Return
10 Year Est. Return
AUM
$101M
AUM Growth
-$5.85M
Cap. Flow
-$5.14M
Cap. Flow %
-5.08%
Top 10 Hldgs %
21.62%
Holding
62
New
Increased
7
Reduced
53
Closed

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$349K
2
ENB icon
Enbridge
ENB
+$315K
3
JPM icon
JPMorgan Chase
JPM
+$247K
4
PRU icon
Prudential Financial
PRU
+$246K
5
GD icon
General Dynamics
GD
+$134K

Top Sells

Rank Stock Value
1
UL icon
Unilever
UL
+$519K
2
AVGO icon
Broadcom
AVGO
+$489K
3
MRK icon
Merck
MRK
+$433K
4
SNA icon
Snap-on
SNA
+$280K
5
GILD icon
Gilead Sciences
GILD
+$134K

Sector Composition

Rank Sector Weight
1 Financials 21.04%
2 Healthcare 15.17%
3 Industrials 11.33%
4 Technology 9.83%
5 Energy 9.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MDT icon
51
Medtronic
MDT
$115B
$1.26M 1.25%
14,353
-828
-5% -$71.3K
VZ icon
52
Verizon
VZ
$196B
$1.25M 1.24%
33,637
-1,674
-5% -$62K
MPC icon
53
Marathon Petroleum
MPC
$92.8B
$1.16M 1.15%
9,990
-617
-6% -$71.7K
UGI icon
54
UGI
UGI
$7.29B
$1.11M 1.1%
41,155
-2,505
-6% -$76.1K
OHI icon
55
Omega Healthcare
OHI
$13.9B
$1.03M 1.02%
33,575
-2,015
-6% -$58.2K
TSN icon
56
Tyson Foods
TSN
$19.8B
$1.02M 1.01%
20,071
-1,231
-6% -$67K
TROW icon
57
T. Rowe Price
TROW
$24.3B
$1M 0.99%
8,955
-548
-6% -$60K
TFC icon
58
Truist Financial
TFC
$63.5B
$810K 0.8%
26,623
-1,702
-6% -$52.9K
KEY icon
59
KeyCorp
KEY
$24.3B
$708K 0.7%
76,658
-4,720
-6% -$49.3K
T icon
60
AT&T
T
$166B
$692K 0.68%
43,406
-2,135
-5% -$36.4K
CAH icon
61
Cardinal Health
CAH
$56.5B
$296K 0.29%
3,133
CI icon
62
Cigna
CI
$72.5B
$224K 0.22%
797

Similar funds

Weaver C. Barksdale & Associates's Q2 2023 Portfolio in Review

As of Q2 2023, Weaver C. Barksdale & Associates held 62 positions worth $101M, down 5.5% from $107M the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Weaver C. Barksdale & Associates withdrew a net $5.14M in Q2 2023, reducing 53 holdings. Its largest reduction was Unilever, cutting an estimated $519K.

By sector, the portfolio is most concentrated in Financials at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Weaver C. Barksdale & Associates added an estimated $349K to Pfizer.

  • Weaver C. Barksdale & Associates added most to Pfizer in Q2 2023, an estimated $349K increase.
  • Weaver C. Barksdale & Associates's biggest Q2 2023 reduction was Unilever, cutting an estimated $519K.
  • Weaver C. Barksdale & Associates's ten largest holdings make up 22% of its $101M portfolio in Q2 2023.
  • Weaver C. Barksdale & Associates opened 0 new positions and closed 0 in Q2 2023.
  • Weaver C. Barksdale & Associates's portfolio value fell 5.5% quarter-over-quarter to $101M.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2023, filed 14 Aug 2023.